BeyondSpring (BYSI) Non-Current Assets (2015 - 2026)
BeyondSpring's (BYSI) quarterly Non-Current Assets came in at $4.7 million in Q2 2026, down 11.76% year-over-year from $5.3 million in Q2 2025, and down 4.02% quarter-over-quarter from $4.9 million in Q1 2026.
Analysis
BeyondSpring (BYSI) Non-Current Assets (2015 - 2026) Analysis & Trends
BeyondSpring has disclosed Non-Current Assets across 12 years of filings, most recently posting $4.7 million for Q2 2026.
- In Q2 2026, Non-Current Assets fell 11.76% year-over-year to $4.7 million; the TTM figure through Jun 2026 stood at $4.7 million (down 11.76% YoY), while the FY2025 annual figure was $5.1 million, down 11.97% from the prior year.
- Non-Current Assets came in at $4.7 million for Q2 2026 at BeyondSpring, down from $4.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $8.0 million in Q2 2022 to a low of $4.7 million in Q2 2026.
- Average Non-Current Assets over 5 years is $6.0 million, with a median of $5.7 million recorded in 2024.
- Year-over-year, Non-Current Assets soared 198.51% in 2022 and declined 17.02% in 2023.
- Over 5 years, Non-Current Assets stood at $7.7 million in 2022, then retreated by 17.02% to $6.4 million in 2023, then slipped by 10.19% to $5.7 million in 2024, then declined by 11.97% to $5.1 million in 2025, then decreased by 6.85% to $4.7 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $4.7 million in Q2 2026, $4.9 million in Q1 2026, and $5.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 159.77 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 113.37 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 294.93 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1.85 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 3.74 Bn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - | 4.71 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.71 Mn |
| Mar 31, 2026 | 4.90 Mn |
| Dec 31, 2025 | 5.05 Mn |
| Sep 30, 2025 | 5.07 Mn |
| Jun 30, 2025 | 5.33 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 5.74 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Dec 31, 2023 | 6.39 Mn |
| Jun 30, 2023 | 7.09 Mn |
| Dec 31, 2022 | 7.70 Mn |
| Jun 30, 2022 | 8.04 Mn |
| Dec 31, 2021 | 6.53 Mn |
| Sep 30, 2021 | 3.70 Mn |
| Jun 30, 2021 | 2.69 Mn |
| Mar 31, 2021 | 2.72 Mn |
| Dec 31, 2020 | 3.64 Mn |
| Sep 30, 2020 | 3.71 Mn |
| Jun 30, 2020 | 3.75 Mn |
| Mar 31, 2020 | 3.75 Mn |